Matches in Wikidata for { <http://www.wikidata.org/entity/Q90772240> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q90772240 description "article scientifique publié en 2019" @default.
- Q90772240 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90772240 description "scientific article published on 14 October 2019" @default.
- Q90772240 description "wetenschappelijk artikel" @default.
- Q90772240 description "наукова стаття, опублікована 14 жовтня 2019" @default.
- Q90772240 name "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 name "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 type Item @default.
- Q90772240 label "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 label "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 prefLabel "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 prefLabel "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 P1433 Q90772240-EDCE4214-20FE-43CC-8E51-3B1C57B81725 @default.
- Q90772240 P1476 Q90772240-CC8D0F62-7C63-4170-A6C5-1BEDF972E44D @default.
- Q90772240 P2093 Q90772240-0B532CA0-324F-492D-B69D-4D045CF92413 @default.
- Q90772240 P2093 Q90772240-0E7A843C-4BE1-4FB2-839B-CCBA249DB2C6 @default.
- Q90772240 P2093 Q90772240-13E65677-E1EF-462B-8875-CA803CF66ACE @default.
- Q90772240 P2093 Q90772240-17D39167-3418-4CBB-BB44-CA429168F8AE @default.
- Q90772240 P2093 Q90772240-3FD4A7A2-2DDC-4F1E-9CAE-CE5ECEC3E022 @default.
- Q90772240 P2093 Q90772240-4EC65BCF-B8BA-4167-9113-7D8679BD0B1E @default.
- Q90772240 P2093 Q90772240-5C5FE95A-3BA7-4883-B005-C348EAEE091B @default.
- Q90772240 P2093 Q90772240-7DA5A19F-9D42-4968-B9B9-A781903C30A4 @default.
- Q90772240 P2093 Q90772240-7FCAD820-2318-4975-8CDA-A7217748238A @default.
- Q90772240 P2093 Q90772240-81998E02-966A-4353-9E16-13B74C13D370 @default.
- Q90772240 P2093 Q90772240-91F2AD6B-E5F8-4FD1-8643-BCF08F6441AF @default.
- Q90772240 P2093 Q90772240-B3B0C693-7646-4D2D-9875-2AB94A2DBC41 @default.
- Q90772240 P2093 Q90772240-BD98470F-8C8B-4764-A577-77F08A367871 @default.
- Q90772240 P2093 Q90772240-DC716741-2CC1-4C30-987B-EC168B228211 @default.
- Q90772240 P2093 Q90772240-E91587DE-8A9A-42AC-9346-3221C15886DE @default.
- Q90772240 P2093 Q90772240-ED5A3D0E-46FE-41C7-AC65-BE6282062288 @default.
- Q90772240 P2093 Q90772240-F5511E22-0277-469D-B4E8-0846453EF87D @default.
- Q90772240 P2093 Q90772240-FC41CC81-6A94-4DD0-9B81-2F5B01E0693C @default.
- Q90772240 P2860 Q90772240-060C1D84-47C7-46E7-87DB-7E3CDB732953 @default.
- Q90772240 P304 Q90772240-020A4B1D-5A2B-45BC-94A6-56AF19D0D5FF @default.
- Q90772240 P31 Q90772240-2E66E9CB-A050-4E87-B03E-A05BEF3E7F6B @default.
- Q90772240 P356 Q90772240-C3F59479-2CFB-4AE5-A927-BB751641B136 @default.
- Q90772240 P433 Q90772240-A08031EA-FE0B-4980-BD7A-6FE8B476242C @default.
- Q90772240 P478 Q90772240-718D61C1-4B58-4DC8-9607-B7293DF1975F @default.
- Q90772240 P50 Q90772240-A2846E09-473A-4438-AA43-440E538EA79A @default.
- Q90772240 P577 Q90772240-E0DCC763-4E24-4EF8-A1DA-86D70C2FEA44 @default.
- Q90772240 P698 Q90772240-B88046F2-96EF-41C5-BDF8-EDC9AD8EFE29 @default.
- Q90772240 P921 Q90772240-A2665ECF-2033-4237-BBAE-D6655F302851 @default.
- Q90772240 P356 J.JTHO.2019.10.003 @default.
- Q90772240 P698 31622732 @default.
- Q90772240 P1433 Q2448056 @default.
- Q90772240 P1476 "A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients" @default.
- Q90772240 P2093 "Aaron M Gruver" @default.
- Q90772240 P2093 "Adolfo Favaretto" @default.
- Q90772240 P2093 "Christian Schumann" @default.
- Q90772240 P2093 "Chun-Ming Tsai" @default.
- Q90772240 P2093 "Eun Kyung Cho" @default.
- Q90772240 P2093 "Gee-Chen Chang" @default.
- Q90772240 P2093 "Giorgio Scagliotti" @default.
- Q90772240 P2093 "Heidrun Grosch" @default.
- Q90772240 P2093 "Jens Kollmeier" @default.
- Q90772240 P2093 "Johan Wallin" @default.
- Q90772240 P2093 "Kambiz Mansouri" @default.
- Q90772240 P2093 "Martin Kimmich" @default.
- Q90772240 P2093 "Matteo Brighenti" @default.
- Q90772240 P2093 "Nicolas Girard" @default.
- Q90772240 P2093 "Sameera R Wijayawardana" @default.
- Q90772240 P2093 "Te-Chun Hsia" @default.
- Q90772240 P2093 "Volker Wacheck" @default.
- Q90772240 P2093 "Xuejing Aimee Wang" @default.
- Q90772240 P2860 Q27851406 @default.
- Q90772240 P304 "80-90" @default.
- Q90772240 P31 Q13442814 @default.
- Q90772240 P356 "10.1016/J.JTHO.2019.10.003" @default.
- Q90772240 P433 "1" @default.
- Q90772240 P478 "15" @default.
- Q90772240 P50 Q57054866 @default.
- Q90772240 P577 "2019-10-14T00:00:00Z" @default.
- Q90772240 P698 "31622732" @default.
- Q90772240 P921 Q3658562 @default.